Papers
3
Total Citations
123
H-Index
3
About
Klaus Baumann is a prominent gynecologic oncologist whose research has made substantial contributions to our understanding of borderline ovarian tumors (BOT), a rare and clinically complex gynecological malignancy. His work centers on improving diagnostic precision, surgical management, and prognostic assessment for patients with this condition. As a key contributor to the multicenter AGO ROBOT study — one of the largest systematic investigations of BOT to date — Baumann helped establish evidence-based standards of care for a disease previously defined by limited retrospective data. His 2014 sub-analysis, now cited over 75 times, revealed critical age-dependent differences in clinical characteristics and outcomes among BOT patients, reshaping how clinicians approach this heterogeneous patient population. His subsequent 2015 study further demonstrated that incomplete surgical staging serves as a negative prognostic factor, providing granular insight into which specific staging procedures carry the greatest clinical significance. Collectively, his publications have garnered significant academic attention, influencing treatment guidelines and clinical practice internationally. Baumann's sustained focus on multicenter collaboration and rigorous central pathology review has elevated the quality of evidence in gynecologic oncology, making his body of work essential reading for researchers and clinicians managing ovarian tumors.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3